Eiry Roberts - 22 Dec 2023 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Reporting relationship: Chief Medical Officer
Issuer ticker: NBIX
Reported as of: 22 Dec 2023
Net transaction value: -$1,267,448
SEC form: 4
Accepted by SEC: 27 Dec 2023, 16:15:43 UTC
Prior SEC filing: 14 Dec 2023
Next SEC filing: 02 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Darin Lippoldt, Attorney-in-Fact

Key filing fact

Eiry Roberts filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 27 Dec 2023.

Key facts

This page summarizes Eiry Roberts's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 27 Dec 2023, 16:15.

Change

Previous filing in this sequence was filed on 14 Dec 2023.
Current net transaction value: -$1,267,448.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBIX transaction

Common Stock

Sale

Transaction value: $1,267,448
Shares: -10,000
Change %: -34%
Price: $126.74
Shares after: 19,521
Date: 22 Dec 2023
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Footnote F2

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $128.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Footnote F3

18,336 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power